# Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC, RATIONALE 302): Impact on Health-Related Quality of Life

Florian Lordick[1], Eric Van Cutsem[2], Ken Kato[3], Jaffer Ajani[4], Lin Shen[5], Tianyu Xia[6], Ningning Ding[7], Lin Zhan[8], Gisoo Barnes[8], Sung-Bae Kim[9]

[1]University of Leipzig Medical Center, University Cancer Center (UCCL), Leipzig, Germany; [2]University Hospitals Gasthuisberg Leuven and KULeuven, Leuven, Belgium; [3]National Cancer Center Hospital, Tokyo, Japan; [4]University of Texas MD Anderson Cancer Center, Houston, TX, USA; [5]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China; [6]BeiGene, Ltd., Cambridge, MA, USA; [7]BeiGene (Shanghai) Co., Ltd., Shanghai, China; [8]BeiGene, Ltd., San Mateo, CA, USA; [9]Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

## Background

- Esophageal squamous cell carcinoma (ESCC) is the most common histological subtype of esophageal cancer, accounting for more than 85% of esophageal cancers worldwide[1, 2]
- Standard second-line therapy for advanced or metastatic ESCC typically consists of single-agent taxane or irinotecan
  - The efficacy of this therapy is limited, with marginal antitumor activity, poor long-term survival, and significant toxicities[2-6]
- Tislelizumab, a monoclonal antibody against PD-1, was specifically engineered to minimize binding to Fcγ receptor on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy
- RATIONALE 302 was a global, open-label, randomized, phase 3 study (NCT03430843) that investigated tislelizumab compared with investigator-chosen chemotherapy (ICC) as second-line treatment for patients with advanced or metastatic ESCC
  - Overall survival was significantly improved with tislelizumab versus ICC (median, 8.6 vs 6.3 months; hazard ratio [HR], 0.70 [95% CI, 0.57-0.85], P=.0001)
  - Treatment with tislelizumab was associated with higher objective response rate (20.3% vs 9.8%) and a more durable antitumor response (median, 7.1 months vs 4.0 months) versus ICC
  - Fewer patients experienced grade ≥3 treatment-related adverse events (18.8% vs 55.8%) with tislelizumab as compared with ICC

## Methods

- The study population consisted of adult patients (aged ≥18 years) with histologically confirmed ESCC who had advanced or metastatic disease which progressed during or after first-line systemic treatment
- Eligible patients were randomized (1:1) to receive tislelizumab (200 mg) IV every 3 weeks or ICC of the following single-agent chemotherapies: paclitaxel, docetaxel, or irinotecan IV on defined schedules. Treatment discontinuation was triggered upon disease progression, intolerable toxicity, or withdrawal for other reasons.
- Health-related quality of life (HRQoL) was a secondary endpoint and was assessed using patient-reported outcomes (PROs) via three validated PRO instruments:
  - The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30)
  - The EORTC Quality of Life Questionnaire Esophageal Cancer Module OES18 (QLQ-OES18)[7]
  - The EuroQoL Five-Dimensions Five-Levels (EQ-5D-5L) Visual Analogue Score (VAS)[8]

### HRQoL Assessments and Endpoints

- The PRO measures were collected at baseline and at every cycle through Cycle 6 or until treatment discontinuation (whichever occurs first)
- The key PRO endpoints included:
  - The EORTC QLQ-C30 Global Health Status/Quality of Life (GHS/QoL), physical functioning, and fatigue scales
  - EORTC QLQ-OES18 index score (total symptoms) dysphagia, reflux, eating, and pain symptom scores
  - Additionally, EQ5D-5L VAS scores were included in the analysis
- Higher scores in GHS/QoL, physical functioning, and VAS, and lower scores in fatigue scales and OES18 symptoms scores indicated better HRQoL outcomes

### Statistical Analyses

- All analyses were conducted using the data cutoff of December 1, 2020
- Completion rate was defined as the number of patients that completed the questionnaire from the total number of patients in the relevant treatment arm
- Adjusted completion rate was defined as the proportion of patients that completed the questionnaire from the total number of patients in the study at the relevant visit in the relevant treatment arm

## Results

### Patient Characteristics

- Patient demographics and baseline disease characteristics are presented in Table 1

**Table 1. Patient Demographics and Baseline Characteristics in the ITT Population**

| | Tislelizumab (n=256) | ICC (n=256) |
|---|---|---|
| **Median age, years (range)** | 62.0 (40-86) | 63.0 (35-81) |
| Patients <65 years, n (%) | 157 (61.3) | 161 (62.9) |
| Patients ≥65 years, n (%) | 99 (38.7) | 95 (37.1) |
| **Sex** | | |
| Male | 217 (84.8) | 215 (84.0) |
| Female | 39 (15.2) | 41 (16.0) |
| **Geographic region** | | |
| Asia | 201 (78.5) | 203 (79.3) |
| Europe/North America | 55 (21.5) | 53 (20.7) |
| **ECOG performance status, n (%)** | | |
| 0 | 66 (25.8) | 60 (23.4) |
| 1 | 190 (74.2) | 196 (76.6) |
| **PD-L1 expression, n (%)** | | |
| vCPS ≥10% | 89 (34.8) | 68 (26.6) |
| vCPS <10% | 116 (45.3) | 140 (54.7) |
| Unknown | 51 (19.9) | 48 (18.8) |
| **Smoking status, n (%)** | | |
| Never | 68 (26.6) | 63 (24.6) |
| Former/Current | 188 (73.4) | 192 (75.0) |
| Missing | 0 (0.0) | 1 (0.4) |
| **Previous therapies, n (%)** | | |
| Surgery | 94 (36.7) | 99 (38.7) |
| Radiotherapy | 169 (66.0) | 163 (63.7) |
| Platinum-based chemotherapy | 249 (97.3) | 252 (98.4) |
| **Disease stage at study entry, n (%)** | | |
| Locally advanced | 5 (2.0) | 20 (7.8) |
| Metastatic | 251 (98.0) | 236 (92.2) |

ECOG, Eastern Cooperative Oncology Group; ICC, investigator-chosen chemotherapy; ITT, intent-to-treat; PD-L1, programmed death-ligand 1; vCPS, visually estimated combined positive score.

---

- Least-squares (LS) mean score change from baseline to Cycle 4 and Cycle 6 was assessed using a mixed model for repeated measurement with the change from baseline in PRO key endpoints score as the response variable treatment; study visit, treatment by study visit interaction, baseline mean score by study visit interaction, and randomization stratification factors (Eastern Cooperative Oncology Group performance status [0 vs 1] and ICC option [paclitaxel vs docetaxel vs irinotecan]) were covariates, based upon "missing at random" assumption
- Mean change from baseline in the EQ-VAS was analyzed descriptively
- Time to deterioration was defined as time to first onset of a ≥10-point change in direction of worsening from baseline with confirmation by a subsequent decrease from baseline, using the Kaplan-Meier method; a stratified Cox model with Efron's method of tie handling was used to assess between-group differences

### Completion Rates

- QLQ-C30, QLQ-OES18, and EQ-5D-5L completion rates at baseline were 93.8% or greater (Table 2)
  - At Cycle 4, the completion rate dropped to 57% in the tislelizumab arm and 30% in the ICC arm
  - At Cycle 6, the completion rate declined to 39% in the tislelizumab arm and 15% in the ICC arm
- For all three measures, the adjusted completion rates remained consistent and was 92% or greater across all assessments

**Table 2. Completion Rates for HRQoL Assessments**

| | Tislelizumab (n=256) | ICC (n=256) |
|---|---|---|
| **EORTC QLQ-C30** | | |
| **Baseline** | | |
| Patients in study at visit, n | 256 | 256 |
| Completion rate, n (%)[a] | 242 (94.5) | 247 (96.5) |
| Adjusted completion rate (%)[b] | 94.5 | 96.5 |
| **Cycle 4** | | |
| Patients in study at visit, n | 157 | 83 |
| Completion rate, n (%)[a] | 147 (57.4) | 77 (30.1) |
| Adjusted completion rate (%)[b] | 93.6 | 92.8 |
| **Cycle 6** | | |
| Patients in study at visit, n | 100 | 39 |
| Completion rate, n (%)[a] | 99 (38.7) | 38 (14.8) |
| Adjusted completion rate (%)[b] | 99.0 | 97.4 |
| **EORTC QLQ-OES18** | | |
| **Baseline** | | |
| Patients in study at visit, n | 256 | 256 |
| Completion rate, n (%)[a] | 240 (93.8) | 248 (96.9) |
| Adjusted completion rate (%)[b] | 93.8 | 96.9 |
| **Cycle 4** | | |
| Patients in study at visit, n | 157 | 83 |
| Completion ratea, n (%) | 146 (57.0) | 76 (29.7) |
| Adjusted completion rate (%)[b] | 93.0 | 91.6 |
| **Cycle 6** | | |
| Patients in study at visit, n | 100 | 39 |
| Completion rate, n (%)[a] | 99 (38.7) | 37 (14.5) |
| Adjusted completion rate (%)[b] | 99.0 | 94.9 |
| **EQ-5D-5L** | | |
| **Baseline** | | |
| Patients in study at visit, n | 256 | 256 |
| Completion rate, n (%)[a] | 242 (94.5) | 248 (96.9) |
| Adjusted completion rate (%)[b] | 94.5 | 96.9 |
| **Cycle 4** | | |
| Patients in study at visit, n | 157 | 83 |
| Completion rate, n (%)[a] | 147 (57.4) | 77 (30.1) |
| Adjusted completion rate (%)[b] | 93.6 | 92.8 |
| **Cycle 6** | | |
| Patients in study at visit, n | 100 | 39 |
| Completion rate, n (%)[a] | 99 (38.7) | 37 (14.5) |
| Adjusted completion rate (%)[b] | 99.0 | 94.9 |

[a]Completion rate = number of patients with completed questionnaire/total number of patients in relevant treatment arm. [b]Adjusted completion rate = number of patients with completed questionnaire/total number of patients in study at relevant visits in relevant treatment arm.
EORTC, European Organization for Research and Treatment of Cancer; EQ-5D-5L, EuroQoL Five-Dimensions Five-Levels; HRQoL, health-related quality of life; ICC, investigator-chosen chemotherapy; QLQ-C30, Quality of Life Questionnaire Core 30; QLQ-OES18, Quality of Life Questionnaire Esophageal Cancer Module OES18.

### EORTC QLQ-C30: Change From Baseline

- Changes from baseline in GHS/QoL (Figure 1) were significantly less at Cycles 4 and 6 in tislelizumab-treated patients compared to the ICC arm
- There were no differences in change from baseline between the arms at Cycle 4 in physical functioning
  - At Cycle 6, the decline in physical functioning from baseline was significantly less in the tislelizumab arm compared to the ICC arm
- Fatigue increased at Cycles 4 and 6 for both tislelizumab and ICC arms
  - At both cycles the increase in fatigue was significantly less in the tislelizumab arm

**Figure 1. Change From Baseline for EORTC QLQ-C30 at Cycle 4 and Cycle 6**



EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; ICC, investigator-chosen chemotherapy; LS, least square; QLQ-C30, Quality of Life Questionnaire Core 30; QoL, quality of life.

### EORTC QLQ-OES18: Change From Baseline

- Change from baseline in the OES18 index, dysphagia, and pain did not differ between the two arms at Cycles 4 and 6 (Figure 2)
- Patients in the tislelizumab arm experienced similar eating symptoms at Cycle 4, but had improvement at Cycle 6 when compared to the ICC arm
- For reflux at Cycle 4, change from baseline was significant, with patients in the tislelizumab arm experiencing fewer reflux symptoms at Cycle 4 as compared to the ICC arm
  - At Cycle 6, patients in both arms experienced similar and slight decreases from baseline in reflux

## Conclusions

- Tislelizumab as a second-line treatment for patients with advanced or metastatic ESCC was associated with more favorable HRQoL outcomes than investigator-chosen chemotherapy
- The general health and quality of life of tislelizumab-treated patients remained stable while ICC-treated patients experienced decline
  - In addition, tislelizumab-treated patients experienced less worsening in physical functioning and fatigue than ICC patients
- Improvements in the disease-specific symptoms of eating and reflux in the tislelizumab arm relative to the ICC arm were observed
- Time to deterioration analysis further showed that through the course of treatment, patients in the tislelizumab arm were at lower risk of clinically meaningful worsening of physical functioning and the disease-related symptom of reflux
- While the results of this study are encouraging, they should be considered alongside the following limitations:
  - First, the current study was an open-label design and had limited follow-up time (eg, through 6 cycles) in assessing change in patients' HRQoL
  - Second, the completion rate of the QLQ-C30 and QLQ-OES18 at Cycles 4 and 6 were markedly lower than at baseline
- Overall, HRQoL was maintained or improved in second-line patients with advanced or metastatic ESCC receiving tislelizumab compared to patients receiving ICC
  - These HRQoL data, together with the efficacy and safety results from the RATIONALE 302 trial, support the favorable risk-benefit ratio for tislelizumab as a second-line therapy for patients with advanced or metastatic ESCC

**Table 3. Change From Baseline for EQ-5D-5L VAS Scores at Cycle 4 and Cycle 6**

| | Tislelizumab (n=256) | | ICC (n=256) | |
|---|---|---|---|---|
| | Observed Mean (SD) | Change From Baseline Mean (SD) | Observed Mean (SD) | Change From Baseline Mean (SD) |
| Baseline | 73.7 (17.05) | | 72.5 (18.13) | |
| Cycle 4 | 77.5 (14.77) | -0.2 (10.91) | 70.8 (17.01) | -1.8 (14.17) |
| Cycle 6 | 78.5 (16.03) | -0.6 (14.81) | 73.8 (16.32) | -5.9 (16.34) |

EQ-5D-5L VAS, EuroQoL Five-Dimensions Five-Levels Visual Analogue Score; ICC, investigator-chosen chemotherapy.

**Table 4. Time to Deterioration for EORTC QLQ-C30 and QLQ-OES18**

| | | Tislelizumab (n=256) | ICC (n=256) |
|---|---|---|---|
| **QLQ-C30 GHS/QoL** | Patients with event, n (%) | 59 (23.0) | 47 (18.4) |
| | Median time to deterioration, months (95% CI) | NR (NE, NE) | NR (NE, NE) |
| | Stratified[1] hazard ratio, 95% CI | 0.96 (0.65, 1.41) | |
| | Stratified[1] log-rank test P value | .4156 | |
| **QLQ-C30 Physical Functioning** | Patients with event, n (%) | 47 (18.4) | 52 (20.3) |
| | Median time to deterioration, months (95% CI) | NR (NE, NE) | 10.0 (4.5, NE) |
| | Stratified[1] hazard ratio, 95% CI | 0.67 (0.45, 1.00) | |
| | Stratified[1] log-rank test P value | .0239 | |
| **QLQ-OES18 Dysphagia** | Patients with event, n (%) | 63 (24.6) | 63 (24.6) |
| | Median time to deterioration, months (95% CI) | NR (3.7, NE) | |
| | Stratified[1] hazard ratio, 95% CI | 0.76 (0.53, 1.07) | |
| | Stratified[1] log-rank test P value | .0562 | |
| **QLQ-OES18 Eating** | Patients with event, n (%) | 35 (13.7) | 27 (10.5) |
| | Median time to deterioration, months (95% CI) | NR (NE, NE) | NR (NE, NE) |
| | Stratified[1] hazard ratio, 95% CI | 1.06 (0.64, 1.75) | |
| | Stratified[1] log-rank test P value | .4158 | |
| **QLQ-OES18 Reflux** | Patients with event, n (%) | 32 (12.5) | 45 (17.6) |
| | Median time to deterioration, months (95% CI) | NR (15.1, NE) | |
| | Stratified[1] hazard ratio, 95% CI | 0.50 (0.32, 0.80) | |
| | Stratified[1] log-rank test P value | .0014 | |
| **QLQ-OES18 Pain** | Patients with event, n (%) | 49 (19.1) | 44 (17.2) |
| | Median time to deterioration, months (95% CI) | NR (NE, NE) | NR (NE, NE) |
| | Stratified[1] hazard ratio, 95% CI | 0.89 (0.59, 1.35) | |
| | Stratified[1] log-rank test P value | .2969 | |

EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; ICC, investigator-chosen chemotherapy; NE, not estimated; NR, not reached; QLQ-C30, Quality of Life Questionnaire Core 30; QLQ-OES18, Quality of Life Questionnaire Esophageal Cancer Module OES18.

**Figure 2. Change From Baseline for QLQ-OES18 Scores at Cycle 4 and Cycle 6**



ICC, investigator-chosen chemotherapy; LS, least square; QLQ-OES18, Quality of Life Questionnaire Esophageal Cancer Module.

### EQ-5D-5L

- At Cycle 4, patients in the tislelizumab arm experienced less decrease in health status according to the VAS score compared with the ICC arm (Table 3)
- At Cycle 6, patients in the tislelizumab arm continued to experience less decrease in health status compared with the ICC Arm

### Time to Deterioration

- Deterioration in physical functioning was experienced by fewer patients in the tislelizumab arm than in the ICC arm (Table 4)
  - Time to deterioration in physical functioning was significantly longer with tislelizumab than chemotherapy
- Deterioration in reflux was experienced by fewer patients in the tislelizumab arm than in the ICC arm
  - Time to deterioration in reflux was significantly longer with tislelizumab than chemotherapy
- There were no significant differences in time to deterioration for GHS/QoL, dysphagia, eating, and pain

### References

1. Wang QL, et al. Clin Epidemiol. 2018;10:717-728.
2. Huang J, et al. Lancet Oncol. 2020;21:832-842.
3. Assersohn L, et al. Ann Oncol. 2004;15:64-69.
4. Ford HE, et al. Lancet Oncol. 2014;15:78-86.
5. Kato K, et al. Lancet Oncol. 2019;20:1506-1517.
6. Kojima T, et al. J Clin Oncol. 2020;38:4138-4148.
7. Blazeby JM, et al. Eur J Cancer. 2003;39:1384-1394.
8. Pickard AS, et al. Med Care. 2007;45:259-263.

### Correspondence

florian.lordick@medizin.uni-leipzig.de